Abstract 149P
Background
Thymic carcinoma(TC) is the most aggressive subtype of thymic epithelial tumors. According to previous clinical trials, immunotherapy was proved to be effective in second line of treatment. Hence a phase II, prospective clinical trial was conducted by our research team to explore the safety and efficacy of toripalimab (a PD-1 inhibitor) combined with chemotherapy as first line treatment in advanced TC.
Methods
We enrolled patients with histologically diagnosis of Masaoka stage III or IV TC. Patients received toripalimab (240mg, d1, q3w) plus paclitaxel (175mg/m2, d1, q3w) and carboplatin (AUC=5, d1, q3w) for 4-6 cycles and continued to receive toripalimab (240mg, d1, q4w) maintenance therapy until disease progression, intolerable toxicity, or withdrawal of consent. The primary endpoint was progression-free survival (PFS). Secondary endpoints were objective response rate (ORR), Disease control rate (DCR), duration of response (DoR), overall survival (OS), time to response (TTR) and safety.
Results
From December 27th, 2020 to June 6th, 2024, 24 patients were enrolled. Median age was 55 years (range: 35–69) and 16 (66.7%) patients were male. 11(45.8%) patients were still on toripalimab maintenance treatment at the time of analysis. For 24 patients received radiological evaluation, best overall response of 8 partial response, 16 stable disease were observed. Accordingly, the ORR was 33.3% and DCR was 100.0%. Median PFS was 25.3 months (95% CI: 14.1-36.5), 1-year PFS rate was 72.0%, 2-year PFS rate was 63.0%. The median follow-up duration was 16.18 months (range: 1.57-41.8). Treatment-related adverse event (TRAE) of any-grade occurred in 23 patients. Grade 3-4 TRAE occurred in 10 patients. The most common grade 3-4 TRAE was neutrophil count decrease. Furthermore, we observed that the patients with lower TMB had more CD8+T cells and CD56dim NK subtype. Patients with PD-L1 TPS≥1% had a higher proportion of M1 type macrophages, suggesting a greater potential for activating antitumor immunity.
Conclusions
Toripalimab combined with chemotherapy is effective and well tolerated as first line treatment for patients with advanced thymic carcinoma.
Clinical trial identification
ChiCTR2000039155.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
7P - ACOX2 disturbs the stability of MRE11-RAD50-NBS1 complex and shapes activated immune tumor microenvironment in clear cell renal cell carcinoma
Presenter: Shiqi Ye
Session: Poster Display session
Resources:
Abstract
9P - CXCR6+PD-1- Tissue Resident memory T cells are associated with poor prognosis in patients with metastatic colorectal cancer
Presenter: Emilien Laloy
Session: Poster Display session
Resources:
Abstract
10P - Tumor-infiltrating lymphocytes and tertiary lymphoid structures in oral cavity squamous cell carcinoma in non-smokers and non-drinkers: Predict clinical outcome
Presenter: Israa Laklouk
Session: Poster Display session
Resources:
Abstract
11P - Tumor-infiltrating lymphocytes on routine H&E staining with automated quantification predict outcomes in resectable non-small cell lung cancer
Presenter: Guus Heuvel
Session: Poster Display session
Resources:
Abstract
12P - Epithelial-mesenchymal transition facilitates response to AXL/PD-1 inhibition in relapsed mesothelioma
Presenter: Essa Baitei
Session: Poster Display session
Resources:
Abstract
14P - Integrated genomic analysis of whole genomes to derive a biomarker of durable response to immunotherapy in melanoma
Presenter: Irene Lobon
Session: Poster Display session
Resources:
Abstract
15P - Verteporfin might potentiate the effects of anti-PD-1 therapy in melanoma-bearing mice model
Presenter: Szonja Kovács
Session: Poster Display session
Resources:
Abstract
16P - Immune checkpoint blockade and HLA-related epistasis in melanoma: Genetic determinants of response and toxicity
Presenter: Martin Little
Session: Poster Display session
Resources:
Abstract
17P - Identification PD-L1-associated lncRNA biomarkers for immunoregulation in ovarian cancer
Presenter: Hee Jung Kim
Session: Poster Display session
Resources:
Abstract
19P - Genetic profiling of early triple-negative breast cancer patients with an indication for neoadjuvant pembrolizumab
Presenter: Bogdan Popescu
Session: Poster Display session
Resources:
Abstract